Inhibikase Therapeutics, Inc.
IKT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001750149
No open-market purchases or sales by Inhibikase Therapeutics, Inc. insiders were filed in the last 90 days; 105 institutions reported holding it in 13F filings for Q2 2026, worth $239.2M in total; no superinvestor holds it.
13F holders, Q2 2026
Institutional positions in Inhibikase Therapeutics, Inc. as of Jun 30, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 105
- +4 vs. Q1 2026
- Shares held
- 117.9M
- +2.74M (+2.4%) vs. Q1 2026
- Total value
- $239.2M
- +$45.8M (+23.7%) vs. Q1 2026
- New holders
- 18
- 47 more added
- Sold out
- 14
- 23 more reduced
3 institutions that held it in Q1 2026 haven't filed for Q2 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q1 2026: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting IKT on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 105 | $239.2M |
| Q1 2026 | 104 | $193.4M |
| Q4 2025 | 74 | $218.2M |
| Q3 2025 | 54 | $89.0M |
| Q2 2025 | 48 | $106.3M |
| Q1 2025 | 47 | $112.7M |
| Q4 2024 | 31 | $162.7M |
| Q3 2024 | 11 | $1.12M |
| Q2 2024 | 12 | $1.02M |
| Q1 2024 | 12 | $443.8K |
| Q4 2023 | 11 | $298.9K |
| Q3 2023 | 13 | $597.6K |
| Q2 2023 | 14 | $2.69M |
| Q1 2023 | 17 | $2.91M |
| Q4 2022 | 19 | $719.4K |
| Q3 2022 | 24 | $2.78M |
| Q2 2022 | 22 | $2.49M |
| Q1 2022 | 24 | $6.33M |
| Q4 2021 | 26 | $6.85M |
| Q3 2021 | 21 | $7.78M |
| Q2 2021 | 14 | $10.6M |
| Q1 2021 | 9 | $975.0K |
Institutions, Q2 2026
Shares, value and share of portfolio for each institution holding Inhibikase Therapeutics, Inc.; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 7,768,057 | $15.8M | 0.00% | +1,464,624+23.2% | Added |
| Fairmount Funds Management LLC | 8,625,000 | $17.5M | 1.16% | 00.0% | Unchanged |
| Trails Edge Capital Partners, LP | 9,051,318 | $18.4M | 2.92% | +993,973+12.3% | Added |
| Soleus Capital Management, L.P. | 10,875,000 | $22.1M | 0.76% | 00.0% | Unchanged |
| Sands Capital Ventures, LLC | 13,018,965 | $26.4M | 4.31% | 00.0% | Unchanged |
| Perceptive Advisors LLC | 0 | $0 | 0.00% | −2,315,000−100.0% | Sold out |
| Ally Bridge Group (NY) LLC | 0 | $0 | 0.00% | −1,325,000−100.0% | Sold out |
| Algert Global LLC | 0 | $0 | 0.00% | −133,830−100.0% | Sold out |
| Point72 Asset Management, L.P. | 0 | $0 | 0.00% | −40,383−100.0% | Sold out |
| Fifth Lane Capital, LP | 0 | $0 | 0.00% | −24,896−100.0% | Sold out |
| Virtu Financial LLC | 0 | $0 | 0.00% | −24,607−100.0% | Sold out |
| CCG Wealth Management, LLC | 0 | $0 | 0.00% | −24,118−100.0% | Sold out |
| Balyasny Asset Management LLC | 0 | $0 | 0.00% | −17,674−100.0% | Sold out |
| Renaissance Technologies LLC | 0 | $0 | 0.00% | −16,500−100.0% | Sold out |
| SG Americas Securities, LLC | 0 | $0 | 0.00% | −15,480−100.0% | Sold out |
| Buckingham Strategic Partners | 0 | $0 | 0.00% | −11,886−100.0% | Sold out |
| Advisor Group Holdings, Inc. | 0 | $0 | 0.00% | −4,000−100.0% | Sold out |
| GAMMA Investing LLC | 0 | $0 | 0.00% | −411−100.0% | Sold out |
| MAI Capital Management | 0 | $0 | 0.00% | −91−100.0% | Sold out |
| CWM, LLC | – | – | – | – | Not filed |
| U.S. Capital Wealth Advisors, LLC | – | – | – | – | Not filed |
| Sunbelt Securities, Inc. | – | – | – | – | Not filed |